News >

Frontline Cabozantinib Plus Nivolumab/Ipilimumab Explored in Phase III RCC Trial

Gina Columbus @ginacolumbusonc
Published: Thursday, May 02, 2019

Gisela Schwab, MD

Gisela Schwab, MD
In an effort to improve outcomes for intermediate- or poor-risk patients with renal cell carcinoma (RCC), the phase III COSMIC-313 trial is being initiated, which will evaluate cabozantinib (Cabometyx) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with previously untreated advanced disease, according to Exelixis, the developer of cabozantinib.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication